Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R
Athena Neurosciences, Inc, South San Francisco, CA 94080, USA.
Ann Neurol. 1995 Oct;38(4):643-8. doi: 10.1002/ana.410380413.
In this clinical study the cerebrospinal fluid (CSF) level of a novel form of the beta-amyloid peptide (A beta) extending to position 42 (A beta 42) was determined in patients with Alzheimer's disease (AD) as well as controls. In addition to measurement of CSF A beta 42 levels, total A beta peptides, microtubule-associated protein tau, and apolipoprotein E (ApoE) genotype were also assessed. It is interesting that CSF A beta 42 levels were found to be significantly lower in AD patients relative to controls, whereas total A beta levels were not. A beta 42 has recently been shown to preferentially deposit in the brain tissue of patients with AD, suggesting that diminished clearance may account for its reduction in CSF. As previously reported, tau levels were increased in AD patients; however, neither A beta 42 nor tau levels were apparently influenced by the ApoE genotype.
在这项临床研究中，测定了阿尔茨海默病（AD）患者以及对照组中一种新的延伸至42位的β-淀粉样肽（Aβ）即Aβ42的脑脊液（CSF）水平。除了测量脑脊液Aβ42水平外，还评估了总Aβ肽、微管相关蛋白tau和载脂蛋白E（ApoE）基因型。有趣的是，发现AD患者脑脊液Aβ42水平相对于对照组显著降低，而总Aβ水平则没有。最近已表明Aβ42优先沉积在AD患者的脑组织中，这表明清除减少可能是其脑脊液中水平降低的原因。如先前报道，AD患者的tau水平升高；然而，Aβ42和tau水平显然均未受ApoE基因型的影响。
